James A. Onori

608 total citations
5 papers, 500 citations indexed

About

James A. Onori is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, James A. Onori has authored 5 papers receiving a total of 500 indexed citations (citations by other indexed papers that have themselves been cited), including 5 papers in Oncology, 3 papers in Molecular Biology and 1 paper in Pulmonary and Respiratory Medicine. Recurrent topics in James A. Onori's work include Angiogenesis and VEGF in Cancer (3 papers), HER2/EGFR in Cancer Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). James A. Onori is often cited by papers focused on Angiogenesis and VEGF in Cancer (3 papers), HER2/EGFR in Cancer Research (3 papers) and PI3K/AKT/mTOR signaling in cancer (3 papers). James A. Onori collaborates with scholars based in United States. James A. Onori's co-authors include Jeffrey A. Stafford, Teresa M. Hopper, L.E. Harrington, Andrea H. Epperly, Mui Cheung, Charles G. Miller, Deirdre K. Luttrell, Rakesh Kumar, Renae M. Crosby and Jennifer H. Johnson and has published in prestigious journals such as Journal of Clinical Oncology, British Journal of Cancer and Molecular Cancer Therapeutics.

In The Last Decade

James A. Onori

5 papers receiving 484 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
James A. Onori United States	4	254	236	224	123	46	5	500
Teresa M. Hopper United States	4	243 1.0×	231 1.0×	204 0.9×	101 0.8×	46 1.0×	6	486
Amogh Boloor United States	5	247 1.0×	219 0.9×	194 0.9×	89 0.7×	46 1.0×	5	500
Maren L. Grazzini United States	6	363 1.4×	278 1.2×	249 1.1×	156 1.3×	55 1.2×	8	629
Steve Bender United States	7	399 1.6×	269 1.1×	259 1.2×	148 1.2×	59 1.3×	9	650
Max Hallin United States	6	362 1.4×	260 1.1×	276 1.2×	142 1.2×	56 1.2×	6	632
Rana Sullivan United States	10	349 1.4×	323 1.4×	259 1.2×	86 0.7×	40 0.9×	19	643
H. Roché France	12	117 0.5×	190 0.8×	303 1.4×	183 1.5×	91 2.0×	24	551
Sönke Korfee Germany	4	359 1.4×	273 1.2×	306 1.4×	154 1.3×	118 2.6×	8	720
Lucia Trandafir Switzerland	11	280 1.1×	272 1.2×	247 1.1×	85 0.7×	61 1.3×	22	634
Jean Powers Canada	9	420 1.7×	265 1.1×	330 1.5×	209 1.7×	53 1.2×	12	748

Countries citing papers authored by James A. Onori

Since Specialization

Citations

This map shows the geographic impact of James A. Onori's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by James A. Onori with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites James A. Onori more than expected).

Fields of papers citing papers by James A. Onori

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by James A. Onori. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by James A. Onori. The network helps show where James A. Onori may publish in the future.

Co-authorship network of co-authors of James A. Onori

This figure shows the co-authorship network connecting the top 25 collaborators of James A. Onori. A scholar is included among the top collaborators of James A. Onori based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with James A. Onori. James A. Onori is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

5 of 5 papers shown

1.

Kumar, Rakesh, Victoria B. Knick, Sharon K. Rudolph, et al.. (2007). Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity. Molecular Cancer Therapeutics. 6(7). 2012–2021. 423 indexed citations

2.

Kumar, Rakesh, L.E. Harrington, Teresa M. Hopper, et al.. (2005). Correlation of anti-tumor and anti-angiogenic activity of VEGFR inhibitors with inhibition of VEGFR2 phosphorylation in mice. Journal of Clinical Oncology. 23(16_suppl). 9537–9537. 10 indexed citations

3.

Dev, I K, Ronna E. Dornsife, Teresa M. Hopper, et al.. (2004). Antitumour efficacy of VEGFR2 tyrosine kinase inhibitor correlates with expression of VEGF and its receptor VEGFR2 in tumour models. British Journal of Cancer. 91(7). 1391–1398. 35 indexed citations

4.

Mullin, Robert J., Doris M. Murray, James A. Onori, & Barry R. Keith. (2004). Xenograft response to combination therapy with the ErbB1-ErbB2 tyrosine kinase inhibitor GW572016.. 64. 882–882. 3 indexed citations

5.

Ignar, Diane M., John L. Andrews, William C. Clay, et al.. (1998). Inhibition of establishment of primary and micrometastatic tumors by a urokinase plasminogen activator receptor antagonist. Clinical & Experimental Metastasis. 16(1). 9–20. 29 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact